Cochrane · systematic review · CD013444
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis
Filippini, G, Minozzi, S, Borrelli, F, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Multiple Sclerosis and Rare Diseases of the CNSAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 22.2%Low 5 · 55.6%Moderate 2 · 22.2%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings table ‐ Cannabis compared to Placebo for health problem or population
Population: health problem or population
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Spasticity: number of participants reporting reduction of 30% in the spasticity NRS ( Summary of findings table ‐ Cannabis vs Placebo | OR 2.51 [1.56, 4.04] | 5 studies · 1143 participants | Moderate Downgraded: risk of bias |
Pain:number of participants reporting pain relief of 50% or greater in the NRS‐PI ( Summary of findings table ‐ Cannabis vs Placebo | OR 4.23 [1.11, 16.17] | 1 study · 48 participants | Very low Downgraded: risk of bias, imprecision |
PGIC:number of participants reporting much or very much improvement in the PGIC ( Summary of findings table ‐ Cannabis vs Placebo | OR 1.8 [1.37, 2.36] | 8 studies · 1215 participants | Moderate Downgraded: risk of bias |
Health‐related quality of life. Mean change from baseline Summary of findings table ‐ Cannabis vs Placebo | no estimate extracted | 8 studies · 1942 participants | Low Downgraded: imprecision |
Withdrawn due to adverse events ( Summary of findings table ‐ Cannabis vs Placebo | OR 2.41 [1.51, 3.84] | 21 studies · 3110 participants | Low Downgraded: risk of bias, imprecision |
SAEs: number of participants with SAEs ( Summary of findings table ‐ Cannabis vs Placebo | OR 1.38 [0.96, 1.99] | 20 studies · 3124 participants | Low Downgraded: risk of bias, imprecision |
Specific AEs:number of participants reporting nervous system disorders ( Summary of findings table ‐ Cannabis vs Placebo | OR 2.61 [1.53, 4.44] | 7 studies · 1154 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Specific AEs: number of participants reporting psychiatric disorders ( Summary of findings table ‐ Cannabis vs Placebo | OR 1.94 [1.31, 2.88] | 6 studies · 1122 participants | Low Downgraded: risk of bias, imprecision |
Specific AEs: number of participants reporting drug tolerance ( Summary of findings table ‐ Cannabis vs Placebo | OR 3.07 [0.12, 75.95] | 2 studies · 458 participants | Very low Downgraded: imprecision |